Premium
LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)
Author(s) -
Duell J,
Maddocks K. J,
GonzálezBarca E,
Jurczak W,
Liberati A. M,
Obr A,
Gaidano G,
Abrisqueta P,
André M,
Dreyling M,
Menne T,
DirnbergerHertweck M.,
Weirather J,
Ambarkhane S,
Salles G
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.28_2879
Subject(s) - medicine , lenalidomide , clinical endpoint , regimen , refractory (planetary science) , gastroenterology , confidence interval , progression free survival , phases of clinical research , neutropenia , surgery , clinical trial , overall survival , chemotherapy , multiple myeloma , physics , astrobiology